AzTrials
AzTrials

Recurrent Urinary Tract InfectionNCT03597152

Nutritional Supplementation for Recurrent Urinary Tract Infections in Women

A study testing WelTract in people with Recurrent Urinary Tract Infection, run by AmPurity Nutraceuticals, LLC.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study will test the ability of specially formulated nutritional supplement capsules to extend the time between recurrent urinary tract infections in women. This objective will be completed by enrolling women who have suffered from 3-4 uncomplicated UTIs in the past 12 months into a double blind placebo controlled… Read more about this study

Who is it for?
Ages 18 to 75 years, women only
Conditions the study is for
Recurrent Urinary Tract Infection
What is being tested?
WelTract
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
250 participants
Where
No sites listed yet
Study dates
1 Aug 2020to 31 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Presenting with symptoms of UTI
  • Presentation of 3rd or 4th simple cystitis of lower tract in the past 12 months
  • Active infection at enrollment, confirmed and documented in medical record
  • Cognitive capacity to consent and ability to undergo the consent process in English

Who cannot join

  • Known allergy or intolerance to supplement ingredients
  • Pregnant or planning to become pregnant or lactating
  • Unwilling to commit to birth control use
  • Use of related nutritional supplements
  • Unwilling to halt berry extracts, polyphenols, antioxidants, d-mannose, vitamins
  • Taken WelTract in past six months
Show all 22Show fewer
  • Unwilling to avoid probiotics, yogurt, apple or cranberry juice, hibiscus tea
  • Certain comorbid or physical conditions
  • History of febrile UTI
  • Bladder catheter or urethral stents
  • Use of topical hormones in urogenital areas
  • Diabetes (i.e. taking diabetic medications) or glycosuria
  • Intestinal diseases with malabsorption (e.g. Crohn's and celiac diseases)
  • Severe renal impairment or kidney stones
  • Neural problems (spinal cord injury or Multiple Sclerosis)
  • Immunocompromised individuals
  • Rheumatoid arthritis
  • Lupus
  • HIV
  • Taking steroids or immunobiologic medications
  • Prophylactic antibiotic use (e.g. post-coital)
  • Other physician judgement

Trial locations and contacts

No sites are listed yet.

About this study

Official title: Nutritional Supplementation for Extending Time Between Recurrent Urinary Tract Infections in Women: a Randomized Double Blind Cross-over Trial

The study will test the ability of specially formulated nutritional supplement capsules to extend the time between recurrent urinary tract infections in women. This objective will be completed by enrolling women who have suffered from 3-4 uncomplicated UTIs in the past 12 months into a double blind placebo controlled cross-over trial. Cross-over and study completion are triggered by the next two UTI recurrences. The goal of the study is for the supplement to extend the time to the next UTI for study participants as compared to placebo.

Read the detailed description

Background: Recurrent urinary tract infections (UTIs), i.e. having three or more infections in 12 months, present a common and serious health problem for women. Long-term prophylactic antibiotic use is one treatment approach though there are currently no consensus treatment strategies for chronic recurrent UTIs which makes development of antibiotic resistant bacterial strains a major concern. Alternatively, nutritional supplements such as those based on cranberry and the sugar d-mannose, have shown some mixed success as a complementary treatment for UTIs. Thus, identification of a multi-ingredient nutritional supplement which could reduce the recurrence of UTIs when applied in conjunction with standard of care would be valuable to the heath and healthcare of women.

Objective: The study will test the efficacy of a twice-daily nutritional supplement for extending the time between recurrent UTIs in women. The supplement is a commercially available product (WelTract, AmPurity LLC) whose capsules contain extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D.

Methods: The study design will be a randomized double-blind placebo-controlled cross-over trial. The primary outcome will be time to recurrence of next UTI. Women (age 18-75 yrs) will be enrolled at a private urology clinic upon presentation of their 3rd or 4th simple cystitis of the lower urinary tract in the past 12 months. Randomization and product consumption will occur concurrently with standard of care treatment (acute antibiotics) of the infection. Resolution of the infection will be confirmed by urine culture and supplement or placebo consumption will continue until UTI recurrence which will trigger cross-over. Again, standard of care will ensue and consumption of the supplement or placebo will continue until UTI recurrence which triggers participant study completion. Cross-over is not forced and the maximum allowable time to cross-over and/or complete the study is one year per participant. Side-effects will be monitored and reported.

Analysis Plan: The study plans to enroll a maximum of 250 women, intending to ensure that 150 women complete the study. Statistical analysis will be performed using both the non-parametric Log Rank test and the Gail and Simon method, each with different primary outputs (statistical significance and effect size, respectively). Both of these methods are suitable for comparing paired time-to-event measures as found in a cross-over design. The baseline sample size (N=150) was calculated using the Cox Proportional Hazard method, at 85% desired power, an alpha level 0.05, a representative hazard ratio of 0.7 from prior cranberry treatment trials, and allowing for up to 40% of the subjects to not complete the study due to reasons such as withdrawal or dropout.

Clinical Significance: The daily consumption of a scientifically-based multi-ingredient nutritional supplement may provide a safe and practical means to extend the time until recurrence of the next UTI for women who have suffered 3-4 UTIs in the past 12 months when applied in combination with standard of care.

Being tested
WelTract, Placebo
Keywords
uncomplicated recurrent urinary tract infection
Medical subject headings
Urinary Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • WelTractDietary supplement

    Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D

  • PlaceboDietary supplement

    Inert placebo custom manufactured for the sponsor

Study groups in NCT03597152
Study groupRoleWhat they receive
TreatmentExperimentalWelTract
Receives: Dietary Supplement: WelTract
ControlPlacebo comparatorInert Placebo
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. UTI Recurrence

    Time to recurrence of next UTI

    Measured: Variable for each participant over course of up to one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2018
  2. Study start1 Aug 2020 (estimated)
  3. Primary completion14 Jan 2022 (estimated)
  4. Study completion31 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
250 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03597152
Sponsor's protocol ID
AMARU 001
Status last verified
Jan 2020
First submitted
13 Jul 2018
Last updated
10 Jan 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023 Nov 10;11(11):CD001321. doi: 10.1002/14651858.CD001321.pub7.

    PubMed 37947276
  • Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023 Apr 17;4(4):CD001321. doi: 10.1002/14651858.CD001321.pub6.

    PubMed 37068952
  • Cooper TE, Teng C, Howell M, Teixeira-Pinto A, Jaure A, Wong G. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD013608. doi: 10.1002/14651858.CD013608.pub2.

    PubMed 36041061

Questions about this trial

What is this clinical trial studying?

A study testing WelTract in people with Recurrent Urinary Tract Infection, run by AmPurity Nutraceuticals, LLC.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Katie O'Brien (501-219-8900 ext. 2002, katie@arkansasurology.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

UTI Recurrence (time frame: Variable for each participant over course of up to one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03597152, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in